Zyprexa Relprevv is a drug owned by Cheplapharm Registration Gmbh. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 30, 2018. Details of Zyprexa Relprevv's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6169084 | 2-methyl-thieno-benzodiazepine formulation |
Sep, 2018
(6 years ago) |
Expired
|
FDA has granted several exclusivities to Zyprexa Relprevv. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zyprexa Relprevv, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zyprexa Relprevv.
Exclusivity Information
Zyprexa Relprevv holds 1 exclusivities. All of its exclusivities have expired in 2012. Details of Zyprexa Relprevv's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2012 |
US patents provide insights into the exclusivity only within the United States, but Zyprexa Relprevv is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zyprexa Relprevv's family patents as well as insights into ongoing legal events on those patents.
Zyprexa Relprevv's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zyprexa Relprevv's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 30, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zyprexa Relprevv Generics:
There are no approved generic versions for Zyprexa Relprevv as of now.
About Zyprexa Relprevv
Zyprexa Relprevv is a drug owned by Cheplapharm Registration Gmbh. It is used for treating psychosis in individuals. Zyprexa Relprevv uses Olanzapine Pamoate as an active ingredient. Zyprexa Relprevv was launched by Cheplapharm in 2009.
Approval Date:
Zyprexa Relprevv was approved by FDA for market use on 11 December, 2009.
Active Ingredient:
Zyprexa Relprevv uses Olanzapine Pamoate as the active ingredient. Check out other Drugs and Companies using Olanzapine Pamoate ingredient
Treatment:
Zyprexa Relprevv is used for treating psychosis in individuals.
Dosage:
Zyprexa Relprevv is available in suspension, extended release form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 210MG BASE/VIAL | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| EQ 300MG BASE/VIAL | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| EQ 405MG BASE/VIAL | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |